Atossa Therapeutics, Inc.
ATOSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. At a $23.9M market cap, Atossa Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Market Cap
$23.9M
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-0.55
EPS (TTM)
$-4.16
EPS (Fwd)
$-4.38
ROE
-78.6%
ROA
-45.5%
Cash
$31.7M
Total Debt
$0
Free CF
-$21.2M
52W Change
-81.4%
Annual Financials
Cash vs Debt
Where ATOS stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, ATOS finished 59.87% below its 150-day moving average ($5.98) and 69.23% below its 200-day moving average ($7.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATOS overbought or oversold?
At the July 14, 2026 close, ATOS's RSI(14) was 73.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Atossa Therapeutics, Inc. reports $31.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$21.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -78.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ATOS.